Clinical Trial Update: An Open-label Study of XEN1101 in Epilepsy [Phase 3]

View source ↗

Summary

An open-label Phase 3 study evaluating XEN1101 for epilepsy is underway, with enrollment by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Focal Epilepsy
• Tonic-clonic Seizures

Drugs mentioned

• XEN1101

Snippet

Sponsor: Xenon Pharmaceuticals Inc. | Conditions: Focal Epilepsy, Tonic-Clonic Seizures | Phase 3 | Status: ENROLLING_BY_INVITATION